Assertio

ASRT

Market cap $77M

SAN FRANCISCO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.

PHILADELPHIA , Sept. 23, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between  March 17, 2022 through September 22, 2022 (the "Class Period").

ATS, ASRT and DBVT have been added to the Zacks Rank #5 (Strong Sell) List on September 23, 2025.

SAN FRANCISCO, Sept. 21, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.

SAN FRANCISCO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- A New York federal court has re-opened the lead plaintiff process in the Spectrum Pharmaceuticals (SPPI) securities class action. This development offers a new opportunity for investors to represent the class after the previously appointed lead plaintiff was disqualified on August 4, 2025. The new deadline to apply is September 24, 2025.

ASRT, CE and ARR have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2025.

PHILADELPHIA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum between March 17, 2022 through September 22, 2022 (the “Class Period”).

ASRT, ARMN and AMRZ have been added to the Zacks Rank #5 (Strong Sell) List on September 16, 2025.

BALTIMORE, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products designed to address patients' needs, today announced new data from a first-ever real-world study of SYMPAZAN (clobazam) Oral Film.

PHILADELPHIA , Sept. 12, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC  is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) ("Spectrum" or the "Company") on behalf of investors who purchased or otherwise acquired common shares of Spectrum between  March 17, 2022 through September 22, 2022 (the "Class Period").